RESUMO
@#<p style="text-align: justify;"><strong>Introduction:</strong> Pneumonia continues to be a leading cause of morbidity and mortality worldwide. Locally, pneumonia is the 3rd cause of death (2016). Currently, one of the concerns is the rise of resistant microorganisms particularly MRSA. Knowledge regarding MRSA pneumonia is mostly from international data. This study aims to determine the factors that may affect the outcome of MRSA and non-MRSA pneumonia as well as describe the susceptibility patterns of its etiologic agents.</p><p style="text-align: justify;"><strong>Methods:</strong> This is a retrospective, cross-sectional cohort study. The setting is a tertiary government hospital. The target subjects are patients 18 y/o and above, with bacteriologically-confirmed pneumonia, and were admitted in 2017.</p><p style="text-align: justify;"><strong>Results:</strong> The results revealed a high rate of MRSA pneumonia (88.2%), most are community-acquired (90%), and factors associated with mortality were: male, Type 2 DM, smoking history, radiographic findings of congestion, and significant difference was noted. For Non-MRSA pneumonia factors associated with mortality were: erythrocytosis, kidney and liver disease, cancer, previous cerebrovascular disease, previous admission (ARMMC), number of comorbidities, findings of altered sensorium, chest retractions, DBP ? 60 mmHg, radiographic findings of pulmonary congestion, and classification of CAP-MR. Morbidity factors included: anemia, trauma, multiple comorbidities, radiographic findings of bilateral infiltrates, unilateral/bilateral consolidation, unilateral/bilateral minimal pleural effusion, subcutaneous emphysema, congestion, and infection with multiple bacteria. The first antibiogram for the institution revealed a poor susceptibility pattern for the usually used empiric treatment.</p><p style="text-align: justify;"><strong>Conclusion:</strong> This study reveals a high rate of MRSA pneumonia, with several factors associated with its mortality. In terms of morbidity, no significant difference was noted from the variables measured. For Non-MRSA pneumonia which is seen in the majority of the subjects, several factors associated with mortality were noted and unlike MRSA pneumonia the morbidity is affected by the presence of anemia, trauma, multiple comorbidities, etc.<br />The antibiogram showed a poor susceptibility to the usually used empiric treatment.</p>
RESUMO
OBJECTIVE:To compare the efficacy and safety of linezolid vs.vancomycin in the treatment of MRSA-inducing ventilator-associated pneumonia in ICU.METHODS:In randomized controlled trials,54 patients with MRSA-inducing ventilator-associated pneumonia in ICU were randomly divided into 2 groups.Linezolid group (n=24) were administered with linezolid 600 mg every 12 h for 10 days,ivgtt.Vancomycin group (n=30) were given vancomycin 500 mg every 8h for 10 days ivgtt.Adverse events and the efficacy of two groups were investigated.RESULTS:Comparison results of linezolid group vs.vancomycin group were as follows:effective rates:100% vs.66.7%,MRSA eradication rates:87.5% vs.43.3%,adverse reactions rates:12.5% vs.13.3%.There were significant differences in the effective rates and MRSA eradication rates between two groups.CONCLUSION:The efficacy and safety of linezolid in the treatment of MRSA-inducing ventilator-associated pneumonia is superior to vancomycin.